Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Accumulated Expenses (2016 - 2026)

Voyager Therapeutics' Other Accumulated Expenses history spans 12 years, with the latest figure at $549000.0 for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 54.29% to $549000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $549000.0, a 54.29% decrease, with the full-year FY2025 number at $549000.0, down 54.29% from a year prior.
  • Other Accumulated Expenses hit $549000.0 in Q4 2025 for Voyager Therapeutics, down from $1.2 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for VYGR hit a ceiling of $7.0 million in Q3 2024 and a floor of $549000.0 in Q4 2025.
  • Historically, Other Accumulated Expenses has averaged $4.0 million across 5 years, with a median of $3.2 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: soared 6543.04% in 2021 and later crashed 62.47% in 2024.
  • Tracing VYGR's Other Accumulated Expenses over 5 years: stood at $5.6 million in 2021, then tumbled by 49.17% to $2.8 million in 2022, then grew by 12.99% to $3.2 million in 2023, then crashed by 62.47% to $1.2 million in 2024, then tumbled by 54.29% to $549000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for VYGR at $549000.0 in Q4 2025, $1.2 million in Q4 2024, and $7.0 million in Q3 2024.